abdominal distentionIncreased riskRR = 0.39, 95% CI: 0.26-0.59
abdominal distention (RR = 0.39, 95% CI: 0.26-0.59)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaconstipationIncreased riskRR = 0.32, 95% CI: 0.18-0.55
constipation (RR = 0.32, 95% CI: 0.18-0.55)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobadiarrheaIncreased riskRR = 0.28, 95% CI: 0.22-0.36
Specifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobanauseaIncreased riskRR = 0.59, 95% CI: 0.36-0.97
nausea (RR = 0.59, 95% CI: 0.36-0.97)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobarashIncreased riskRR = 0.49, 95% CI: 0.28-0.86
rash (RR = 0.49, 95% CI: 0.28-0.86)
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobaOverall tolerabilityReported
S. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62).
from: Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on HelicobadiarrhoeaReportedRR = 0.46; 95% CI: 0.22-0.93; Z = 2.15; p = 0.03
pronounced reductions in diarrhoea (n = 2,091; RR = 0.46; 95% CI: 0.22-0.93; Z = 2.15; p = 0.03)
from: Efficacy and Safety of Saccharomyces Boulardii with Standard Quadruple Therapy for EradicarashReportedRR = 0.33; 95% CI: 0.14-0.77; Z = 2.55; p = 0.01
and rash occurrence (n = 1,271; RR = 0.33; 95% CI: 0.14-0.77; Z = 2.55; p = 0.01)
from: Efficacy and Safety of Saccharomyces Boulardii with Standard Quadruple Therapy for Eradicatreatment-related adverse eventsReportedRR = 0.46; 95% CI: 0.28-0.74; Z = 3.16; p = 0.002
the probiotic combination also substantially reduced treatment-related adverse events (n = 2,183; RR = 0.46; 95% CI: 0.28-0.74; Z = 3.16; p = 0.002)
from: Efficacy and Safety of Saccharomyces Boulardii with Standard Quadruple Therapy for Eradica